Log in

Relevant bibliographies by topics / Drug-sparing regimen / Journal articles

To see the other types of publications on this topic, follow the link: Drug-sparing regimen.

Journal articles on the topic 'Drug-sparing regimen'

Author: Grafiati

Published: 8 June 2024

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Drug-sparing regimen.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Rosa, Rossana, Jose F. Suarez, Marco A. Lorio, et al. "Impact of antiretroviral therapy on clinical outcomes in HIV+ kidney transplant recipients: Review of 58 cases." F1000Research 5 (December 21, 2016): 2893. http://dx.doi.org/10.12688/f1000research.10414.1.

Full text

Abstract:

Background: Antiretroviral therapy (ART) poses challenging drug-drug interactions with immunosuppressant agents in transplant recipients. We aimed to determine the impact of specific antiretroviral regimens in clinical outcomes of HIV+ kidney transplant recipients. Methods: A single-center, retrospective cohort study was conducted at a large academic center. Subjects included 58 HIV- to HIV+ adult, first-time kidney transplant patients. The main intervention was ART regimen used after transplantation. The main outcomes assessed at one- and three-years were: patient survival, death-censored gra

APA, Harvard, Vancouver, ISO, and other styles

2

Dutta, Noton K., Abdullah Alsultan, Thomas J. Gniadek, et al. "Potent Rifamycin-Sparing Regimen Cures Guinea Pig Tuberculosis as Rapidly as the Standard Regimen." Antimicrobial Agents and Chemotherapy 57, no. 8 (2013): 3910–16. http://dx.doi.org/10.1128/aac.00761-13.

Full text

Abstract:

ABSTRACTStrategies involving new drug combinations, as well as new uses of existing drugs, are urgently needed to reduce the time required to cure patients with drug-sensitive or multidrug-resistant (MDR) tuberculosis (TB). We compared the sterilizing activity of the standard first-line antitubercular regimen, rifampin-isoniazid-pyrazinamide (RHZ), with that of the novel regimen PA-824–moxifloxacin–pyrazinamide (PaMZ), which is currently being studied in clinical trials (NCT01498419), in the guinea pig model of chronic TB infection, in which animals develop necrotic granulomas histologically r

APA, Harvard, Vancouver, ISO, and other styles

3

Ruzicka, Daniel J., Mayuko Kamakura, Naho Kuroishi, et al. "Characteristics of 2-drug regimen users living with HIV-1 in a real-world setting: A large-scale medical claim database analysis in Japan." PLOS ONE 17, no. 6 (2022): e0269779. http://dx.doi.org/10.1371/journal.pone.0269779.

Full text

Abstract:

Background Regimen simplification to 2-drug antiretroviral therapy (2-ART) may address potential tolerability issues, increase adherence, and reduce toxicity and potential drug-drug-interactions among people living with HIV-1 (PLWH). However, real-world treatment patterns and characteristics of 2-ART users are unclear. Methods This retrospective observational cohort study employed a large-scale medical claim database of Japanese hospitals to extract data on 4,293 PLWH aged ≥18 years with diagnosis of HIV and treated with any ART regimens between April 2008 and April 2019. A 2-ART cohort was co

APA, Harvard, Vancouver, ISO, and other styles

4

Maggiolo, Franco, Nicola Gianotti, Laura Comi, et al. "Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial." Antiviral Therapy 26, no. 3-5 (2021): 51–57. http://dx.doi.org/10.1177/13596535211042226.

Full text

Abstract:

Background Primary analysis at 24 weeks showed that switching to rilpivirine plus darunavir/cobicistat was non-inferior to continuing a standard three-drug antiretroviral regimen in virologically suppressed people with HIV. We present efficacy and safety data from the 48-week analysis. Methods PROBE 2 is a randomized, open-label trial. Adults who were on a three-drug therapy and had had <50 HIV-1 RNA copies/mL for at least 6 months were randomly assigned (1:1) to 25 mg rilpivirine plus 800/150 darunavir/cobicistat once daily (early switch group) or to continue their regimen for 24 weeks bef

APA, Harvard, Vancouver, ISO, and other styles

5

Sleeper, Rebecca B. "Antipsychotic Dose-Sparing Effect with Addition of Memantine." Annals of Pharmacotherapy 39, no. 9 (2005): 1573–76. http://dx.doi.org/10.1345/aph.1g207.

Full text

Abstract:

OBJECTIVE: To describe a case of an antipsychotic-sparing effect achieved after the addition of memantine to the regimen of a patient with severe Alzheimer's disease and aggressive behavioral disturbances. CASE SUMMARY: A 78-year-old white man with severe Alzheimer's disease was receiving risperidone 2 mg 3 times daily for persistent aggressive and dangerous behavioral disturbances. Memantine was initiated, and the dose was titrated to 10 mg twice daily. The patient's response included improvement in functional status and resolution of problematic behaviors, allowing repeated reduction of the

APA, Harvard, Vancouver, ISO, and other styles

6

Tiberi, Simon, Marie-Christine Payen, Giovanni Sotgiu, et al. "Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB." European Respiratory Journal 47, no. 4 (2016): 1235–43. http://dx.doi.org/10.1183/13993003.02146-2015.

Full text

Abstract:

No large study has ever evaluated the efficacy, safety and tolerability of meropenem/clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/clavulanate added to a background regimen when treating MDR- and XDR-TB cases.Patients treated with a meropenem/clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/clavulanate-sparing regimen (n=168): in the former gr

APA, Harvard, Vancouver, ISO, and other styles

7

Fischl, Margaret A., Ann C. Collier, A. Lisa Mukherjee, et al. "Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen." AIDS 21, no. 3 (2007): 325–33. http://dx.doi.org/10.1097/qad.0b013e328011ddfa.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Karoney, Mercy Jelagat, Mathew Kirtptonui Koech, Evangeline Wawira Njiru, and Willis Dixon Owino Ong’or. "Proximal tubular renal dysfunction among HIV infected patients on Tenofovir versus Tenofovir sparing regimen in western Kenya." PLOS ONE 17, no. 9 (2022): e0273183. http://dx.doi.org/10.1371/journal.pone.0273183.

Full text

Abstract:

Introduction Tenofovir Disoproxil Fumarate (TDF) is the most widely used Anti-Retroviral Therapy (ART) drug due to its potency, safety profile and World Health Organization (WHO) recommendation. TDF causes proximal tubular renal dysfunction (PTRD) leading to Fanconi syndrome, acute kidney injury and chronic kidney disease. Modest rates (2–4%) of TDF related toxicity based on estimated Glomerular Filtration Rate (GFR) have been described, while TDF-induced PTRD has been reported to be 22%. TDF toxicity is more likely among African patients, it is reversible and TDF may be renal dosed in patient

APA, Harvard, Vancouver, ISO, and other styles

9

Stürmer, Martin, Schlomo Staszewski, and Hans Wilhelm Doerr. "Quadruple Nucleoside Therapy with Zidovudine, Lamivudine, Abacavir and Tenofovir in the Treatment of HIV." Antiviral Therapy 12, no. 5 (2007): 695–704. http://dx.doi.org/10.1177/135965350701200514.

Full text

Abstract:

Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality in HIV-infected patients. However, problems such as short-term or long-term toxicity and the development of drug resistance could necessitate a change in the therapy regimen. Whereas various HAART options with low pill burden and favourable long-term tolerability profiles are available for naive patients, treatment of experienced patients tends to be more complex and remains a challenge. Treatment with class sparing nucleoside-only regimens could be an option in this context, but the combination of z

APA, Harvard, Vancouver, ISO, and other styles

10

Kovalskaya, Galina N., Dina Y. Zhukova, and Ekaterina N. Mikhalevich. "Interaction of Drugs Used for the Treatment of Cardiovascular Diseases." Acta Biomedica Scientifica 4, no. 1 (2019): 36–42. http://dx.doi.org/10.29413/abs.2019-4.1.6.

Full text

Abstract:

Combined therapy in cardiology is currently the most recognized method of treatment, especially in patients with hypertension. Approximately in 50 % of patients with hypertension, monotherapy is effective. However to achieve the desired effect in the remaining half of patients, simultaneous administration of two and sometimes three drugs is required. Numerous drugs with a fixed combination of two (and even three) antihypertensive drugs, often used in clinical practice, greatly simplify the dosage regimen of drugs and improve patients’ adherence to treatment. Unfortunately, simultaneous prescri

APA, Harvard, Vancouver, ISO, and other styles

11

Dwyer, Dominic E., Cassy Workman, Gillian Hales, et al. "Enfuvirtide in HIV-1-Infected Individuals Changing Therapy to A Nucleoside Reverse Transcriptase Inhibitor Sparing Regimen: The Alliance Study." Antiviral Therapy 11, no. 4 (2005): 409–19. http://dx.doi.org/10.1177/135965350601100406.

Full text

Abstract:

The role of the fusion inhibitor enfuvirtide in nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimens was assessed in an open-label study of fifty-nine highly antiretroviral drug exposed HIV-1-infected individuals. There was a reduction in plasma HIV-1 RNA of 1.43 (95% confidence interval [CI]: -2.06, -1.22) log10 copies/ml plasma over 96 weeks, and 44% (95% CI: 31, 58) of individuals had a viral load less than 400 copies/ml. A viral load below detection at 96 weeks was predicted by a baseline genotypic sensitivity score greater than 1. There was an average increase of 67 cells/μl

APA, Harvard, Vancouver, ISO, and other styles

12

Rabin, Bradford C., Kristina Reid, Tian-Zhi Guo, Eva Gustafsson, Chousheng Zhang та Mervyn Maze. "Sympatholytic and Minimum Anesthetic Concentration-sparing Responses are Preserved in Rats Rendered Tolerant to the Hypnotic and Analgesic Action of Dexmedetomidine, a Selective α2-adrenergic Agonist". Anesthesiology 85, № 3 (1996): 565–73. http://dx.doi.org/10.1097/00000542-199609000-00016.

Full text

Abstract:

Background The development of tolerance to the sympatholytic and anesthetic-reducing effects of alpha(2) agonists after prolonged administration of dexmedetomidine and how the number of available alpha(2) adrenoceptors affects these dexmedetomidine-induced responses was studied. Methods The sympatholytic action of acute and chronic (3 and 10 micrograms.kg-1.h-1 for 7 days) dexmedetomidine, was assessed by the decrease in norepinephrine turnover in the locus coeruleus and hippocampus. The anesthetic-reducing effect of chronic (7 days) dexmedetomidine (5 and 10 micrograms.kg-1.h-1) was studied b

APA, Harvard, Vancouver, ISO, and other styles

13

Lewis, David A. "New treatment options for Neisseria gonorrhoeae in the era of emerging antimicrobial resistance." Sexual Health 16, no. 5 (2019): 449. http://dx.doi.org/10.1071/sh19034.

Full text

Abstract:

Neisseria gonorrhoeae, the causative agent of gonorrhoea, has rapidly evolved from an exquisitely susceptible pathogen into a ‘superbug’ with the capacity to exhibit an extensively drug resistant (XDR) phenotype. The threat of untreatable gonorrhoea now looms on the horizon while the arsenal of effective antimicrobial agents diminishes with time. Ceftriaxone remains the mainstay of first-line therapy as a single agent or as the backbone of a dual therapy regimen. The implementation of new assays to facilitate ‘precision’ treatment, based on the prediction of N. gonorrhoeae susceptibility to ol

APA, Harvard, Vancouver, ISO, and other styles

14

Autar, Reshma S., Mark A. Boyd, Ferdinand WMN Wit, et al. "Relationships between Drug Exposure, Changes in Metabolic Parameters and Body Fat in HIV-Infected Patients Switched to a Nucleoside Sparing Regimen." Antiviral Therapy 12, no. 8 (2007): 1265–72. http://dx.doi.org/10.1177/135965350701200813.

Full text

Abstract:

Background The pathogenesis of metabolic disturbances in treated HIV infection is incompletely understood. Methods Relationships between fasted metabolic parameters, body composition, and drug plasma concentrations were investigated in 59 patients who switched from failed nucleoside analogue treatment to ritonavir-boosted indinavir and efavirenz therapy. Metabolic parameters, peripheral fat, visceral adipose tissue (VAT) and drug plasma concentrations were measured prospectively. Results Ritonavir exposure was found to be negatively correlated with high-density lipoprotein cholesterol (HDL-c)

APA, Harvard, Vancouver, ISO, and other styles

15

Brugière, Olivier, Alexandre Vallée, Quentin Raimbourg, et al. "Conversion to belatacept after lung transplantation: Report of 10 cases." PLOS ONE 18, no. 3 (2023): e0281492. http://dx.doi.org/10.1371/journal.pone.0281492.

Full text

Abstract:

Background Calcineurin inhibitors (CNIs) remain the cornerstone of maintenance immunosuppression (IS) after lung transplantation (LTx), although CNI-related life-threatening toxic effects may occur. Belatacept, a novel immunosuppressant that blocks a T-cell co-stimulation pathway, is a non-nephrotoxic drug indicated as an alternative to CNIs in kidney Tx. In LTx, there are only a few reports of belatacept conversion as a CNI-free or CNI-sparing IS treatment. Methods We reviewed a series of 10 LTx recipients with conversion to a CNI-free belatacept IS regimen within the first year post-LTx (n =

APA, Harvard, Vancouver, ISO, and other styles

16

Sultan, Mamoona, Adeena Khan, Syed Shahid Habib, and Dheyab Abdulsalam. "Unique clinical spectrum with distinguishing diagnostic features in Vogt-Koyanagi-Harada syndrome." BMJ Case Reports 12, no. 12 (2019): e231397. http://dx.doi.org/10.1136/bcr-2019-231397.

Full text

Abstract:

A 36-year-old ulcerative colitis male patient on treatment for 7 years was referred to dermatology with resistant alopecia universalis and hypopigmented patches on limbs for 5 months. During this time he also reported to ophthalmology with acute bilateral decreased vision for 5 days. His examination revealed hyperaemic discs, multifocal retinal detachments and choroidal granulomas. Taking into account the revised diagnostic criteria, atypical course of disease in the form of early cutaneous presentation followed by ophthalmic manifestations was attributed to Vogt-Koyanagi-Harada syndrome (VKHS

APA, Harvard, Vancouver, ISO, and other styles

17

Cancilla, Daniel, Daniel P. Nurse, Christina Ferraro, Craig S. Sauter, and Jack Khouri. "Comparison of Adverse Effects of Two Mobilization Regimens for Autologous Hematopoietic Cell Transplant in Multiple Myeloma." Blood 144, Supplement 1 (2024): 7259. https://doi.org/10.1182/blood-2024-209019.

Full text

Abstract:

Background: Autologous hematopoietic cell transplantation (HCT) is a standard of care after induction therapy for multiple myeloma (MM). Hematopoietic progenitor cell (HPC) mobilization typically uses G-CSF with or without the CXCR4 antagonist plerixafor (P). Although P has been shown to increase the effectiveness of mobilization, it can be associated with side effects; most commonly GI upset. Due to its high cost, our HPC collection algorithm was updated in an effort to reduce the use of P. The criteria for initiating P became more stringent and far fewer patients were initiated on P prior to

APA, Harvard, Vancouver, ISO, and other styles

18

Delyagin, Wassili M., and Inna V. Lukjanova. "Heart failure in children and adolescents (high yield topics for primary care pediatrician)." Pediatrics. Consilium Medicum, no. 3 (September 15, 2021): 277–84. http://dx.doi.org/10.26442/26586630.2021.3.200998.

Full text

Abstract:

HF in children is a life-threatening polyethiological state with a tendency to progression. There are acute and chronic heart failure, the causes of which are largely determined by age. Depending on the causes and features of hemodynamics, HF can occur with a stored (and borderline) and with a reduced ejection fraction. In early and young childhood, HF is manifested primarily by a decrease in appetite, sweating, decreased physical activity and a slowdown in physical development. At an older age, shortness of breath, edema, and enlargement of the liver are highlighted. The determination of bioc

APA, Harvard, Vancouver, ISO, and other styles

19

Hong, H., D. W. Dowdy, K. E. Dooley, et al. "Risk of hearing loss among multidrug-resistant tuberculosis patients according to cumulative aminoglycoside dose." International Journal of Tuberculosis and Lung Disease 24, no. 1 (2020): 65–72. http://dx.doi.org/10.5588/ijtld.19.0062.

Full text

Abstract:

SETTING: The ototoxic effects of aminoglycosides (AGs) lead to permanent hearing loss, which is one of the devastating consequences of multidrug-resistant tuberculosis (MDR-TB) treatment. As AG ototoxicity is dose-dependent, the impact of a surrogate measure of AG exposure on AG-induced hearing loss warrants close attention for settings with limited therapeutic drug monitoring.OBJECTIVE: To explore the prognostic impact of cumulative AG dose on AG ototoxicity in patients following initiation of AG-containing treatment for MDR-TB.DESIGN: This prospective cohort study was nested within an ongoin

APA, Harvard, Vancouver, ISO, and other styles

20

Kast, Richard E., Marc-Eric Halatsch, and Rafael Rosell. "OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs." Cells 10, no. 5 (2021): 1148. http://dx.doi.org/10.3390/cells10051148.

Full text

Abstract:

Background: Pharmacological targeting aberrant activation of epidermal growth factor receptor tyrosine kinase signaling is an established approach to treating lung adenocarcinoma. Osimertinib is a tyrosine kinase approved and effective in treating lung adenocarcinomas that have one of several common activating mutations in epidermal growth factor receptor. The emergence of resistance to osimertinib after a year or two is the rule. We developed a five-drug adjuvant regimen designed to increase osimertinib’s growth inhibition and thereby delay the development of resistance. Areas of Uncertainty:

APA, Harvard, Vancouver, ISO, and other styles

21

Totiger, Tulasigeri M., Anirban Ghoshal, Jenna Zabroski, et al. "Targeted Therapy Development in Acute Myeloid Leukemia." Biomedicines 11, no. 2 (2023): 641. http://dx.doi.org/10.3390/biomedicines11020641.

Full text

Abstract:

Therapeutic developments targeting acute myeloid leukemia (AML) have been in the pipeline for five decades and have recently resulted in the approval of multiple targeted therapies. However, there remains an unmet need for molecular treatments that can deliver long-term remissions and cure for this heterogeneous disease. Previously, a wide range of small molecule drugs were developed to target sub-types of AML, mainly in the relapsed and refractory setting; however, drug resistance has derailed the long-term efficacy of these as monotherapies. Recently, the small molecule venetoclax was introd

APA, Harvard, Vancouver, ISO, and other styles

22

Kim, You Sun. "Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators." Journal of the Korean Medical Association 64, no. 9 (2021): 596–604. http://dx.doi.org/10.5124/jkma.2021.64.9.596.

Full text

Abstract:

Background: Recently, the incidence and prevalence rates of inflammatory bowel disease (IBD) have increased worldwide, including in Korea. Although there has been considerable progress in the management of IBD following the discovery of biologic agents, 5-aminosalicylate (5-ASA) and immunomodulators are still considered cornerstones in the management of mild to moderate IBD.Current Concepts: 5-ASA plays a key role in inducing remission in patients with mild to moderate ulcerative colitis. High doses of 5-ASA are more effective in inducing remission in patients with moderate ulcerative colitis,

APA, Harvard, Vancouver, ISO, and other styles

23

Eisbruch, Avraham, John M. Robertson, Carolyn M. Johnston, et al. "Bromodeoxyuridine Alternating With Radiation for Advanced Uterine Cervix Cancer: A Phase I and Drug Incorporation Study." Journal of Clinical Oncology 17, no. 1 (1999): 31. http://dx.doi.org/10.1200/jco.1999.17.1.31.

Full text

Abstract:

PURPOSE: Preclinical studies show a significant increase in the ratio of the radiosensitizer bromodeoxyuridine (BUdR) in tumors versus the intestinal mucosa during the drug elimination period, compared with the ratio during drug infusion. We constructed a phase I study in patients with locally advanced cervix cancer, using alternating cycles of BUdR and radiation therapy (RT). PATIENTS AND METHODS: Eighteen patients with stage IIB to IVA cervix cancer participated. A treatment cycle consisted of a 4-day BUdR infusion followed by a week of pelvic RT, 15 Gy twice daily in 1.5-Gy fractions. After

APA, Harvard, Vancouver, ISO, and other styles

24

Sher, Taimur, Kena C. Miller, Sikander Ailawadhi, et al. "Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study." Blood 114, no. 22 (2009): 618. http://dx.doi.org/10.1182/blood.v114.22.618.618.

Full text

Abstract:

Abstract Abstract 618 Introduction: Steroids have been an important component of multiple myeloma (MM) therapeutics. High doses steroids as used in MM are associated with significant toxicity and morbidity. Development of steroid independent or steroid-lite regimens remains an important area of investigation in MM. Orlowski et al combined Doxil (D) with bortezomib (V) and showed enhanced anti-myeloma activity. In a phase II study in relapsed refractory MM patients, we observed further improvement in clinical efficacy with addition of thalidomide (T) to VD combination (VDT regimen). Encouraged

APA, Harvard, Vancouver, ISO, and other styles

25

Horvath, Lena, and Andreas Pircher. "ASCO 2020 non-small lung cancer (NSCLC) personal highlights." memo - Magazine of European Medical Oncology 14, no. 1 (2021): 66–69. http://dx.doi.org/10.1007/s12254-020-00673-2.

Full text

Abstract:

SummaryIn this article we summarize our personal non-small cell lung cancer (NSCLC) highlights of the virtual ASCO 2020 meeting, covering developments in early and advanced-stage NSCLC. Until recently early stage NSCLC patients were treated independently of their genetic profile. Now the ADAURA study proved that postoperative osimertinib significantly prolongs disease-free survival compared to standard chemotherapy in EGFR-mutated NSCLC , underlining the high efficacy of targeted therapies in early stages. In advanced-stage disease, of course immunotherapy (IO) was at the center of attention.

APA, Harvard, Vancouver, ISO, and other styles

26

Law, Lisa Y., Ryan Stevenson, Gwendolyn Ho, Bijay Nair, Asakura Laura, and Antoine Sayegh. "Venetoclax-Based Regimen for Treatment of Patients with Acute Myeloid Leukemia in Community Based Practices." Blood 134, Supplement_1 (2019): 5081. http://dx.doi.org/10.1182/blood-2019-121816.

Full text

Abstract:

Introduction: There are limited options for acute myeloid leukemia (AML) patients who are too frail to receive intensive induction chemotherapy or who have relapsed /refractory disease. Early phase II trials published in 2016 demonstrated promising outcomes in AML with the BCL-2 inhibitor venetoclax, which was FDA approved in November 2018. We conducted a retrospective review of AML patients who received venetoclax at Kaiser Permanente Northern California (KPNC) specifically examining patients' characteristics and outcomes. Methods: This is a retrospective review of all KPNC patients who had a

APA, Harvard, Vancouver, ISO, and other styles

27

Finn, Jonathan D., Patricia Favaro, J. Fraser Wright, Federico Mingozzi, Katherine A. High, and Valder R. Arruda. "Rabbit Anti-Thymocyte Globulin (rATG) Administrated Concomitantly with Liver Delivery of AAV2-hFIX Can Promote Inhibitor Formation In Rhesus Macaques." Blood 116, no. 21 (2010): 3765. http://dx.doi.org/10.1182/blood.v116.21.3765.3765.

Full text

Abstract:

Abstract Abstract 3765 Adeno-associated viral (AAV) vectors are one of the most extensively studied vector platforms for gene therapy applications. Our group is currently developing AAV vectors for the therapeutic treatment of hemophilia B (HB) in humans. The first clinical trial using an AAV2 vector to express human Factor IX (hFIX) (AAV2-hFIX16) from the liver of HB patients revealed a cytotoxic T lymphocyte (CTL) response directed against AAV capsid that occurred 4–6 weeks following treatment that was associated with a decline in transgene expression. Thus, immunosuppressive (IS) therapies

APA, Harvard, Vancouver, ISO, and other styles

28

Dybkær, Karen, Hanne Due, Rasmus Froberg Brøndum, Ken H. Young, and Martin Bøgsted. "Addition of Drug-Response Specific Micro-RNAs to the International Prognostic Index Improves Prognostic Stratification of GCB-DLBCL Patients Treated with R-CHOP." Blood 134, Supplement_1 (2019): 1623. http://dx.doi.org/10.1182/blood-2019-122351.

Full text

Abstract:

Background: Patients with Diffuse large B-cell lymphoma (DLBCL) in approximately 40% of cases suffer from primary refractory disease and treatment induced immuno-chemotherapy resistance demonstrating that standard provided treatment regimens are not sufficient to cure all patients. Early detection of resistance is of great importance and defining microRNA (miRNA) involvement in resistance could be useful to guide treatment selection and help monitor treatment administration while sparing patients for inefficient, but still toxic therapy. Concept and Aims: With information on drug-response spec

APA, Harvard, Vancouver, ISO, and other styles

29

Soon, Gaik H., Ping Shen, Eu-Leong Yong, Paul Pham, Charles Flexner, and Lawrence Lee. "Pharmacokinetics of Darunavir at 900 Milligrams and Ritonavir at 100 Milligrams Once Daily when Coadministered with Efavirenz at 600 Milligrams Once Daily in Healthy Volunteers." Antimicrobial Agents and Chemotherapy 54, no. 7 (2010): 2775–80. http://dx.doi.org/10.1128/aac.01564-09.

Full text

Abstract:

ABSTRACT Ritonavir-boosted darunavir with efavirenz may be considered a nucleoside-sparing regimen for treatment-naïve HIV-infected patients. However, the pharmacokinetics of this combination administered once daily have not been studied. We conducted a three-period interaction study with healthy volunteers. The subjects were given darunavir at 900 mg with ritonavir at 100 mg once daily for 10 days. Efavirenz at 600 mg once daily was added for 14 days. Darunavir-ritonavir was then stopped and efavirenz alone was given for 14 days. At the end of each period, blood was taken predosing and for u

APA, Harvard, Vancouver, ISO, and other styles

30

Sapountzi, Evdoxia, Eleni P. Kotanidou, Vasiliki-Rengina Tsinopoulou, Lampros Fotis, Liana Fidani, and Assimina Galli-Tsinopoulou. "The Management of IgG4-Related Disease in Children: A Systematic Review." Children 12, no. 2 (2025): 213. https://doi.org/10.3390/children12020213.

Full text

Abstract:

Background/Objectives: IgG4-related disease (IgG4-RD) is a multi-organ disease with greatly varying therapeutic approaches and a lack of specific treatment algorithms. This systematic review aimed to determine the therapeutic approaches for pediatric IgG4-RD in real-word practice. Methods: We searched PubMed and Google Scholar for articles on pediatric IgG4-RD cases published in English from 2012 to August 2024, focusing on treatments and outcomes. Study type, treatment(s), dose/regimen, age and sex, organ(s) involved, and treatment outcomes were manually extracted from each study. Results: Of

APA, Harvard, Vancouver, ISO, and other styles

31

Ng, Loke, Yeo, Chng, and Tan. "A Meta-Analysis of the Utility of Preoperative Intravenous Paracetamol for Post-Caesarean Analgesia." Medicina 55, no. 8 (2019): 424. http://dx.doi.org/10.3390/medicina55080424.

Full text

Abstract:

Background and objectives: Worldwide, the number of caesarean sections performed has increased exponentially. Some studies have reported better pain control and lower postoperative requirements for opioids when intravenous (IV) paracetamol was administered preoperatively. This meta-analysis thus aimed to investigate the utility of preoperative IV paracetamol for post-caesarean analgesia. Materials and Methods: By using the keywords (paracetamol OR acetaminophen) AND [cesarea* OR caesarea* OR cesaria* OR caesaria*], a systematic literature search was conducted using PubMed, Medline, Embase, Goo

APA, Harvard, Vancouver, ISO, and other styles

32

Jeny, Florence, Hilario Nunes, and Dominique Valeyre. "Current Medical Therapy for Sarcoidosis." Seminars in Respiratory and Critical Care Medicine 38, no. 04 (2017): 523–31. http://dx.doi.org/10.1055/s-0037-1604032.

Full text

Abstract:

AbstractMost cases of sarcoidosis are mild and self-limited, with a spontaneous cure. However, in some patients, this disease may also be life-threatening, particularly when severe manifestations induce vital organ dysfunction. Sarcoidosis may also severely impair the quality of life through diverse, persistent disabling symptoms. To date, there is no curative treatment for sarcoidosis, but only anti-inflammatory drugs limiting the pathologic impact of sarcoidosis in reducing enhanced immunity reactions, granulomatous formation, and their consequences. Current anti-inflammatory treatments for

APA, Harvard, Vancouver, ISO, and other styles

33

S., Sivakumar, and Banupriya K. "Monitoring of adverse drug reactions caused by methotrexate at the dermatology department of a tertiary care centre." International Journal of Research in Dermatology 3, no. 3 (2017): 389. http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20173078.

Full text

Abstract:

<p class="abstract"><strong>Background:</strong> <span lang="EN-IN">Dermatologists are using antineoplastic agent methotrexate for more than six decades for various skin diseases. Methotrexate is a dihydrofolate reductase inhibitor and has cytotoxic<strong>,</strong> anti-inflammatory and steroid sparing effect. However, long term use of methotrexate raises a concern about its safety. Careful monitoring of patients on methotrexate therapy can either minimize or prevent the adverse effects.</span><span lang="EN-IN">The aim of the study was to eval

APA, Harvard, Vancouver, ISO, and other styles

34

Lauretti, Gabriela R., Izabel C. P. R. Lima, Marlene P. Reis, Wiliam A. Prado, and Newton L. Pereira. "Oral Ketamine and Transdermal Nitroglycerin as Analgesic Adjuvants to Oral Morphine Therapy for Cancer Pain Management." Anesthesiology 90, no. 6 (1999): 1528–33. http://dx.doi.org/10.1097/00000542-199906000-00005.

Full text

Abstract:

Background Guidelines for cancer pain management include nonsteroidal antiinflammatory drugs with opioids administered in a time-contingent manner. This study was designed to evaluate the role of oral ketamine or transdermal nitroglycerin polymer, a nitric oxide donor, as coadjuvants to oral morphine in cancer pain therapy. Methods After institutional approval and informed patient consent were obtained, 60 patients with cancer pain were randomized to one of four groups (n = 15) and studied prospectively to evaluate analgesia and any adverse effects. A visual analog scale that consisted of a 10

APA, Harvard, Vancouver, ISO, and other styles

35

Gandola, L., M. Nantron, A. Marchianò, et al. "Outcome in stage IV Wilms tumor treated according to the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) trials." Journal of Clinical Oncology 27, no. 15_suppl (2009): 10031. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.10031.

Full text

Abstract:

10031 Background: Children with metastases at diagnosis for Wilms tumor (WT) still display a worse prognosis compared to localized disease. Methods: We analyzed survival results in patients with stage IV WT enrolled in the AIEOP CNR92 and TW2003 clinical trials (3/1992–3/2008). Treatment strategy across these trials evolved in terms of sparing whole lung radiotherapy (RT) in case of complete disappearance of lung metastases after primary chemotherapy and a doxorubicin cumulative dose reduction from 360 mg/m2 to 240 mg/m2 in TW2003. Results: Of 553 in-study patients aged less than 18 years, 68

APA, Harvard, Vancouver, ISO, and other styles

36

Mironov, S. P., M. B. Cykunov, G. M. Burmakova, and S. V. Andreev. "Lumbosacral pain in athletes and ballet dancers: spondylolysis and spondylolisthesis. Conservative treatment." N.N. Priorov Journal of Traumatology and Orthopedics 27, no. 1 (2020): 11–18. http://dx.doi.org/10.17816/vto202027111-18.

Full text

Abstract:

The aim of the study was to develop an algorithm for conservative treatment of lumbosacral pain syndrome (PCBS) caused by spondylolysis in athletes and ballet dancers. Materials and methods. The study included 212 patients athletes and ballet dancers with PCBS caused by spondylolysis (171 people) and grade III spondylolisthesis (41 people) of the lumbar vertebrae. Clinical, neurological, and X-ray studies, ultrasonography, computed tomography, scintigraphy, functional testing, as well as markers of bone resorption (calcium in urine) and bone formation (alkaline phosphatase) were performe

APA, Harvard, Vancouver, ISO, and other styles

37

Pei, Xin-Yan, Michael W. Sanderson, Leena E. Youssefian, et al. "Bcl-2 Antagonism Potentiates MEK1/2/Chk1 Inhibitor Lethality in Multiple Myeloma Cells Overexpressing Bcl-2 through a Stat3-Dependent Mechanism." Blood 124, no. 21 (2014): 4763. http://dx.doi.org/10.1182/blood.v124.21.4763.4763.

Full text

Abstract:

Abstract Introduction: Multiple myeloma (MM) is characterized by deregulation of members of the Bcl-2 family of apoptotic regulatory proteins. This has led to the development of BH3-mimetics such as ABT-737 which inhibits Bcl-2/xL but not Mcl-1. Previously, we reported that simultaneous inhibition of Chk1 and MEK1/2 dramatically induced apoptosis in cultured and primary MM cells, including cells resistant to conventional agents, while sparing their normal counterparts (Pei et al., Blood 2007, 2011). Recently, we reported that this strategy circumvented MM cell resistance conferred by overexpre

APA, Harvard, Vancouver, ISO, and other styles

38

van der Lee, Miranda M. C., Tanja van Achterberg, Kaylee Hersmus, et al. "Abstract 3129: BYON4413, an in vivo active CD123-targeting antibody-drug conjugate, combines effectively with azacitidine and venetoclax in acute myeloid leukemia cell lines." Cancer Research 84, no. 6_Supplement (2024): 3129. http://dx.doi.org/10.1158/1538-7445.am2024-3129.

Full text

Abstract:

Abstract Background: CD123, the alpha chain of the interleukin-3 receptor (IL-3Rα), is overexpressed in multiple hematologic malignancies and found particularly highly expressed on the surface of acute myeloid leukemia (AML) cells. Furthermore, increased CD123 expression on leukemic stem cells relative to non-neoplastic hematopoietic stem cells makes CD123 an attractive tumor-associated target for an antibody-drug conjugate (ADC). BYON4413 is an ADC that consists of a novel humanized IgG1 anti-CD123 antibody site-specifically conjugated with Byondis' proprietary duocarmazine linker-drug techno

APA, Harvard, Vancouver, ISO, and other styles

39

Winkler, K., G. Beron, G. Delling, et al. "Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response." Journal of Clinical Oncology 6, no. 2 (1988): 329–37. http://dx.doi.org/10.1200/jco.1988.6.2.329.

Full text

Abstract:

Following observation of the predictive value of the histologic extent of tumor cell destruction after preoperative chemotherapy for metastasis-free survival (MFS) in osteosarcoma, a randomized study was undertaken with the aim of (1) sparing some patients the unpleasant side effects of highly toxic drugs like doxorubicin (DOX) and cisplatin (CPDD) by administering these drugs postoperatively only after poor response with a milder preoperative regimen, and (2) improving the prognosis of patients responding poorly to the initial treatment by use of a salvage chemotherapy postoperatively. The av

APA, Harvard, Vancouver, ISO, and other styles

40

Liguori, Nicholas R., Ashley Fss Uruchurtu, Young Lee, et al. "Abstract 4064: Synergistic activity of Lurbinectidin plus ONC201 in SCLC is associated with ATF4, CHOP and pChk1 induction." Cancer Research 82, no. 12_Supplement (2022): 4064. http://dx.doi.org/10.1158/1538-7445.am2022-4064.

Full text

Abstract:

Abstract Small cell lung cancer (SCLC) accounts for 15% of lung cancer and is responsive to chemotherapy but most patients relapse with drug-resistant disease and have very poor 5-year survival of less than 7%. One of the most notable advances in the last decade has been the approval of lurbinectedin for platinum resistant SCLC. Lurbinectedin is a small molecule inhibitor, targeting RNA polymerase II, and binding the minor grooves of DNA to induce double-strand breaks. The dismal SCLC survival rate underscores the need for a novel combination to increase patient survival outcomes. ONC201 is a

APA, Harvard, Vancouver, ISO, and other styles

41

Xi, Simon, Patricia Soulard, Kai Li, et al. "Effect of RGT-61159 on inhibition of oncogene c-MYB synthesis and tumor growth inhibition in a broad range of ACC PDX models, at well tolerated doses in rodents and non-human primates." Journal of Clinical Oncology 42, no. 16_suppl (2024): 6107. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.6107.

Full text

Abstract:

6107 Background: RGT-61159 is a first in-class oral inhibitor of the oncogenic transcription factor c-MYB via selective alteration of its RNA splicing machinery. RGT-61159 selectively induces the inclusion of the cryptic “poison” exon into the c-MYB RNA transcripts, resulting in the robust elimination of c-MYB canonical mRNA transcript and consequently of its protein in cells. Overactivation of the c-MYB oncogene, primarily due to chromosome rearrangements, is a hallmark of adenoid cystic carcinoma. (ACC). ACC is a rare and aggressive type of cancer for which effective treatment does not exist

APA, Harvard, Vancouver, ISO, and other styles

42

Normant, Emmanuel, Marcelo Lima Ribeiro, Nuria Profitos-Peleja, et al. "The Ublituximab-Umbralisib (U2) Drug Regimen Potentiates the Activity of the Novel CD47-CD19 Bispecific Antibody, TG-1801, through the Activation of the G Protein-Coupled Receptor EBI2/GPR183." Blood 138, Supplement 1 (2021): 1196. http://dx.doi.org/10.1182/blood-2021-150570.

Full text

Abstract:

Abstract Introduction: TG-1801 is a novel, bispecific anti-CD47 and anti-CD19 fully human IgG1 antibody that targets CD47 selectively on CD19+ B-cells, sparing red blood cells or platelets and blocking the CD47-SIRPα macrophage checkpoint on mature B cells. TG-1801 is currently in clinical trial as a single agent or in combination with ublituximab, a glyco-engineered CD20 antibody, in B-cell non-Hodgkin lymphoma (B-NHL). The doublet therapy of ublituximab with the dual PI3Kδ/CK1e inhibitor umbralisib ("U2" regimen), provides a non-chemotherapy backbone regimen on which several novel multidrug

APA, Harvard, Vancouver, ISO, and other styles

43

Lu, Norman, Patricia Soulard, Kay Li, et al. "Abstract 3306: RGT-M001, a first-in-class small molecule mRNA degrader of the oncogenic transcription factor c-Myb, demonstrated remarkable single agent anti-tumor efficacy in cancer patient-derived xenograft model." Cancer Research 84, no. 6_Supplement (2024): 3306. http://dx.doi.org/10.1158/1538-7445.am2024-3306.

Full text

Abstract:

Abstract Dysregulated transcription factors (TFs) represent a unique class of drug targets that drive aberrant gene expression programs involved in the major hallmarks of cancers. However, developing drug-like small molecules targeting TF proteins for clinical purposes has proven to be extremely challenging. Here, we present a novel and innovative approach to degrade the RNA transcript of the master oncogenic transcription factor C-MYB, thereby preventing its undesirable expression, using potent and orally available small molecules. C-MYB is a transcription factor that regulates differentiatio

APA, Harvard, Vancouver, ISO, and other styles

44

Deisher, Theresa, Margaret Taylor, Arya Ashok, et al. "AVM0703, a New Treatment Option for Lymphoma Patients." Blood 134, Supplement_1 (2019): 5308. http://dx.doi.org/10.1182/blood-2019-128812.

Full text

Abstract:

AVM0703 is a new treatment option for lymphoma patients that can eliminate or reduce the dose of standard chemotherapy in the overall treatment plan. Radiation and chemotherapy have dramatically improved survival for patients with cancer. However, the American Cancer Society has reported that chemotherapy and radiation increase the chances of secondary cancers. In fact, the report states that chemotherapy is known to be a higher risk factor than radiation in causing leukemia. The need to decrease chemotherapy administration in young adults and pediatric populations becomes even more essential

APA, Harvard, Vancouver, ISO, and other styles

45

Hamilton, Erika Paige, Manish R. Patel, Jordi Rodon, et al. "Masterkey-01: Phase I/II, open-label multicenter study to assess safety, tolerability, pharmacokinetics, and antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies." Journal of Clinical Oncology 38, no. 15_suppl (2020): TPS3665. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps3665.

Full text

Abstract:

TPS3665 Background: A significant unmet need exists for drugs targeting allosteric ErbB mutations (non-canonical mutations outside the ATP binding site). Current EGFR and HER2 tyrosine kinase inhibitors or mAbs have limited antitumor activity against allosteric mutations, resulting in toxicity before adequate drug exposure (Connell and Doherty, 2017). BDTX-189 is a potent and selective orally available irreversible inhibitor targeting unique oncogenic driver mutations of ErbB kinases in EGFR and HER2, while sparing WT EGFR. Preclinical studies demonstrated antitumor activity across a range of

APA, Harvard, Vancouver, ISO, and other styles

46

Puoti, Massimo, Alessandro Cozzi-Lepri, Fausto Ancarani, et al. "The Management of Hepatitis B Virus/HIV-1 Co-Infected Patients Starting Their First Haart Regimen. Treating Two Infections for the Price of One Drug?" Antiviral Therapy 9, no. 5 (2004): 811–17. http://dx.doi.org/10.1177/135965350400900506.

Full text

Abstract:

We examined the impact of a lamivudine-containing highly active antiretroviral therapy (HAART) regimen on 164 hepatitis B virus/HIV co-infected individuals starting their first HAART. Lamivudine-treated patients (accounting for 73% of the study population) showed a significantly lower level of alanine aminotransferase over follow-up [–81.1 mU/ml mean difference; 95% confidence intervals (95% CI): –30.3; –131.7, P=0.003] and a significantly reduced risk of liver-related morbidity/mortality [Relative hazard (RH)=0.07; 95% CI: 0.01–0.38, P=0.002] than those starting a lamivudine sparing-regimen.

APA, Harvard, Vancouver, ISO, and other styles

47

Dai, Yun, Shuang Chen, Xin-Yan Pei, et al. "Targeting CDK9 Dramatically Potentiates ABT-737-Induced Apoptosis in Human Multiple Myeloma Cells through a Bim-Dependent Mechanism." Blood 114, no. 22 (2009): 297. http://dx.doi.org/10.1182/blood.v114.22.297.297.

Full text

Abstract:

Abstract Abstract 297 Background: High expression of the anti-apoptotic Bcl-2 family protein Mcl-1 is a critical survival mechanism in human multiple myeloma (MM) cells, and a key barrier to apoptosis induced by the Bcl-2/-xL antagonist ABT-737. De novo expression of the short-lived protein Mcl-1 is controlled transcriptionally by CDK9, a catalytic subunit of the PTEF-b transcription elongation complex (CDK9/cyclin T) that phosphorylates the C-terminal domain (CTD) of RNA polymerase II (RNA pol II) to promote elongation of nascent transcripts. Thus, approaches targeting CDK9 may enhance ABT-73

APA, Harvard, Vancouver, ISO, and other styles

48

diCapua Siegel, David Samuel, Thomas Martin, Michael Wang, et al. "Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)." Blood 116, no. 21 (2010): 985. http://dx.doi.org/10.1182/blood.v116.21.985.985.

Full text

Abstract:

Abstract Abstract 985 Introduction: CFZ is a novel and highly selective epoxyketone proteasome inhibitor currently in clinical development for the treatment of multiple myeloma (MM). Ph 1 and 2 studies with CFZ have demonstrated durable single-agent antitumor activity in pts with relapsed or refractory (R/R) MM. The present study, PX-171-003-A1, was an open-label, single-arm Ph 2b trial and enrolled patients with multiply relapsed MM whose disease was refractory (defined as <25% response on, or progression during or <60 days after completion of, therapy) to their last treatment regimen.

APA, Harvard, Vancouver, ISO, and other styles

49

Howard, Caleigh, Shu Wiley, Wenzhao Dong, et al. "Abstract 335: c-KIT targeted ETBs for cancer therapy and HSC transplant conditioning." Cancer Research 82, no. 12_Supplement (2022): 335. http://dx.doi.org/10.1158/1538-7445.am2022-335.

Full text

Abstract:

Abstract Engineered toxin bodies (ETBs) are next-generation immunotoxins that harbor an antibody-derived targeting domain and a cytotoxic payload derived from Shiga-like toxin-1 catalytic subunit A (SLTA). SLTA has been engineered to reduce innate immunogenicity and therefore increase the safety of ETBs whilst retaining potent cytotoxic properties. When targeted via a binding domain, SLTA is internalized and routes to the cytosol leading to irreversible ribosome inactivation and ultimately cell death. ETBs have been developed to treat a wide variety of cancers, including breast, lymphoma, mult

APA, Harvard, Vancouver, ISO, and other styles

50

Marcelin, A. G., B. Visseaux, M. Wirden, et al. "NRTI-sparing regimens yield higher rates of drug resistance than NRTI-based regimens for HIV-1 treatment." Journal of Global Antimicrobial Resistance 2, no. 2 (2014): 103–6. http://dx.doi.org/10.1016/j.jgar.2013.12.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!